Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an orchid herb help tame prediabetes?

NCT ID NCT07704944

Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests whether Bletilla formosana (BF), a traditional Chinese herbal medicine from a Taiwanese ground orchid, can safely help control blood sugar and reduce inflammation in adults with prediabetes. Prediabetes is a condition where blood sugar is higher than normal but not yet diabetic, often leading to type 2 diabetes. Participants are randomly assigned to take a high dose, low dose, or placebo powder for 12 weeks, with blood tests to monitor safety and effects on glucose and inflammation markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a traditional Chinese medicinal herb called Bletilla formosana (BF), given as a powder
What this could lead to
If it works, this could point toward a natural supplement to help manage prediabetes and reduce the risk of developing type 2 diabetes.
What could go wrong
This is an early pilot trial with only 94 people, so results may not apply broadly. The herb's effectiveness and safety are not yet proven, and it may not outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 94 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 30-70 years. 2. Prediabetes defined by any of the following: 3. Fasting Plasma Glucose (FPG) of 100-125 mg/dL, or 4. Glycated hemoglobin (HbA1c) of 5.7%-6.4%. 5. Willingness to provide written informed consent and comply with study procedures. Exclusion Criteria: 1. Established type 1 or type 2 diabetes mellitus, or recent use of oral antidiabetic agents or insulin (within 3 months). 2. Abnormal liver function, defined as Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) exceeding 2-fold the upper reference limit (≥2 × ULN) at screening. 3. Abnormal renal function, defined as serum creatinine (Cr) \>1.5 mg/dL or Estimated Glomerular Filtration Rate (eGFR) \<60 mL/min/1.73 m². 4. Gastrointestinal disorders that may affect drug absorption, such as gastrostomy, enterostomy, severe chronic diarrhea, or malabsorption syndrome. 5. Severe comorbidities within the past 6 months, including major stroke, myocardial infarction, major trauma, or major surgery. 6. Recent use of medications (within 1 month) that may significantly alter blood glucose or lipids, such as systemic corticosteroids or non-stable doses of lipid-lowering agents. 7. Malignant tumor under active treatment, or immunodeficiency/autoimmune disorders requiring immunosuppressive therapy. 8. Psychiatric disorders or cognitive impairment that may affect protocol compliance. 9. Active use of other investigational drugs within 3 months prior to screening. 10. Pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prediabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Keelung Chang Gung Memorial Hospital

    Keelung, 204, Taiwan

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, 333, Taiwan

  • Taoyuan Chang Gung Memorial Hospital

    Taoyuan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.